Cognito Therapeutics

The American Medical Association’s (AMA) to ease access to remote Cognitive Behavioral Therapy Monitoring

by

The Dig­i­tal Ther­a­peu­tics Alliance Wel­comes Deci­sion by the CPT® Edi­to­r­i­al Pan­el to Clar­i­fy Report­ing of Remote Cog­ni­tive Behav­ioral Ther­a­py Mon­i­tor­ing Ser­vices (press release):

As the lead­ing inter­na­tion­al orga­ni­za­tion on dig­i­tal ther­a­peu­tic thought lead­er­ship and edu­ca­tion, the Dig­i­tal Ther­a­peu­tics Alliance (DTA) wel­comes the Amer­i­can Med­ical Association’s (AMA) Cur­rent Pro­ce­dur­al Ter­mi­nol­o­gy (CPT®) Edi­to­r­i­al Pan­el’s recent deci­sion to clar­i­fy report­ing of remote cog­ni­tive behav­ioral ther­a­py (CBT) mon­i­tor­ing ser­vices. The changes to the CPT code set reflect the grow­ing recog­ni­tion that dig­i­tal ther­a­peu­tics (DTx) are an effec­tive treat­ment for patients with men­tal health con­di­tions and physi­cians should ulti­mate­ly be reim­bursed for their time spent pre­scrib­ing, mon­i­tor­ing, and sup­ply­ing online CBT tech­nolo­gies. [Read more…] about The Amer­i­can Med­ical Association’s (AMA) to ease access to remote Cog­ni­tive Behav­ioral Ther­a­py Monitoring

Neurostimulation device GammaSense by Cognito Therapeutics secures FDA Breakthrough Device Designation to explore Alzheimer’s Disease applications

by

Cred­it: The Picow­er Insti­tute @ MIT

Cog­ni­to Ther­a­peu­tics nets FDA break­through label for light, sound ther­a­py for Alzheimer’s dis­ease (Fierce Biotech):

Using spe­cif­ic fre­quen­cies of flash­ing lights and sounds to stim­u­late the brain’s elec­tri­cal activ­i­ty, Cog­ni­to Ther­a­peu­tics believes it can help treat Alzheimer’s dis­ease by ener­giz­ing neu­rons and reac­ti­vat­ing the immune system.

[Read more…] about Neu­rostim­u­la­tion device Gam­maSense by Cog­ni­to Ther­a­peu­tics secures FDA Break­through Device Des­ig­na­tion to explore Alzheimer’s Dis­ease applications